The FDA has initiated daily publication of adverse event reports via its Adverse Event Reporting System, transitioning from quarterly updates to enhance public accessibility and safety monitoring. The agency’s Commissioner, Marty Makary, emphasized this as a critical move to reduce delays in safety signal identification. Meanwhile, the NIH published a detailed plan to implement enhanced scientific standards focusing on reproducibility, transparency, and unbiased research. These regulatory shifts underscore increasing emphasis on research integrity and post-market drug safety surveillance.